Tim Wang

Expert en IA améliorant les soins de santé @UHN, fan de science-fiction, papa de chien 🐾🚀

[Int Society of Nephrology @ISNkidneycare]

🎙️ Join us LIVE for an #XSpace on Kidney Care in Indigenous Populations in recognition of the International Day of the World's Indigenous Peoples.

Hear global experts discuss kidney health disparities, culturally appropriate care, and strategies to advance equitable kidney care for Indigenous communities.

📅 August 7
⏰ 2 pm CEST
🔗 Set a reminder: https://t.co/7r0vqnUMUT
#IndigenousPeoplesDay #KidneyHealth #ThisIsISN

[Journal of Invasive Cardiology @InvasiveCardiol]

From the Coronary Imaging Topic Center 🔎 CCTA to Guide Percutaneous Coronary Intervention: Proceedings From the 1st CCTA-Guided PCI Summit in the US

Read here: https://t.co/9lm0oLAxed

@yadersandoval @DLBHATTMD #cardioTwitter #cardioX #cardiology #interventionalcardiology

[thmonk @thmonk_pf]

前臨床AD 1778名でAtrophy Network Mappingを施行
従来法で陰性でもAD認知症類似nttwork萎縮を検出
総萎縮/tauと部分独立に認知/機能低下を予測しAβ依存

OA

#Alzheimers
#network
#papers
https://t.co/MU4J0TOzV8

[USC Urology @USC_Urology]

The project, led by Evgeniy Kreydin, will combine advanced brain imaging, clinical bladder testing, and a noninvasive therapy called transcutaneous spinal cord stimulation. The researchers aim to identify imaging biomarkers, or measurable features seen on brain scans, that can help predict which stroke survivors are most likely to benefit from the treatment. https://t.co/NEyIL6onfJ #uscurology #stroke #nih #urinaryincontinence

[Twist Bioscience @TwistBioscience]

WES, WGS, what? Considering whole exome sequencing (WES) or whole genome sequencing (WGS)?

This great article featuring input from our CEO and co-founder (and chemist!) @EmilyLeproust has some fantastic tips for making the right choice: https://t.co/D0Yj4meyNK

[Hao Yin @HaoYin20]

Histone AcetylTransferases P300 & CBP have distinct functional roles in Arterial Smooth Muscle Cell phenotypes

P300 pro-contractile, working with TET2
CBP pro-migratory, working with HADC2/5

Converging on H3K9/27ac-SRF-Myocardin-SMC contractile gene transcription

@KathyMartinYale @CircAHA 2022
https://t.co/uRH6Lr10YI

[EURETINA @EURETINA]

NEW PODCAST: Inside Euretina Innovation Spotlight: Retina, Industry & Regulators

Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei talk about the Euretina Innovation Spotlight that returns to Vienna on 30 September.

🎧 Listen now: https://t.co/ocWHivJ148

[Hong Jae Chon @hongjaechon]

🚨 Ate/Bev vs Durva/Treme in 1L advanced HCC: Which regimen to choose in real-world practice?
A new TriNetX global real-world study (N=1,530 PSM pairs) published in @JGHofficial
👉 Overall Survival: Comparable (mOS 14.6 vs 17.3 mo; aHR 0.96, p=0.62)
👉 Treatment-requiring irAEs: Significantly lower with Ate/Bev (20.2% vs 24.6%, aHR 0.61, p<0.001)
👉 Bleeding & HTN: Broadly comparable between groups.
DOI: https://t.co/5JPf8730SI
@ILCAnews @EASLnews @myESMO #HCC #Immunotherapy #TriNetX

[China Science @ChinaScience]

The Shenzhou-23 astronauts have reached their 60th day in orbit aboard China's space station, carrying out a range of tasks, including multiple scientific experiments, maintenance of the space station complex platform, and in-orbit health management. Recent highlights include:
- A study on gut microbiome changes as a result of long-duration spaceflight
- A force control test to investigate the patterns of fine motor control changes and adaptive learning mechanisms during long-term orbital missions
- Image recognition exercises under various initial conditions using a metacognitive training system

[Drew Moghanaki @DrewMoghanaki]

Lots of hope for SGLT2 inhibitors to treat early stage lung cancers. Especially when they’re still just a GGO.

[Drew Moghanaki @DrewMoghanaki]

An extraordinary environment for lung cancer researchers.

[Razia Aliani @RaziaAliani]

Want FREE tips on using AI in research?
↳ Join 18K+ researchers here ⬇️
🔗 https://t.co/WZfOGQtKzs

[Razia Aliani @RaziaAliani]

Your next research paper might be read by 200
A 60-second explanation of it could reach 200,000.

Nature just said something academia may not be ready to hear:

Scientists in the future will not read articles like this.
That sounds extreme.

Until you look at how younger generation already consume information:

- Short videos.
- Creator-led explanations.
- Algorithmic feeds.

That changes the job of a researcher.

Publishing may increasingly be only half the job.

Making the research understandable may become the other half.

🔗 of this interesting article in thread

[Vivek Subbiah, MD @VivekSubbiah]

⭐️An AI co-scientist to accelerate biomedical research.
⭐️The AI agent Biomni performs research tasks across diverse biomedical fields; with further training and optimization, it could be a powerful research partner for scientists @NatureMedicine @OncoAlert
https://t.co/FvCT99iorh

[Giuseppe Galati @GiuseppeGalati_]

🔥 Cardiac myosin-binding protein C in
community-based patients with suspected
heart failure

🩸 measurement of #cMyBP-C, a novel biomarker of chronic myocar­dial injury, improved the diagnostic accuracy #NTproBNP in patients with suspected HF in the community.

✅The additive value was greatest in the detection of HFrEF.

⬆️ #cMyBP-C concentrations were asso­ciated with a ⬆️ risk of HF hospitalization or death, including after adjustment for #NTproBNP.

🔬 The measurement of #cMyBP-C, in addition to #NTproBNP, may help in the prioritization of echocardiography for pts with suspected HF

🫀 @HFUAcademy 🍀

https://t.co/0dFvFm9NeT

@EJHFEiC @HFA_President @gpontone1 @chiarabd @MicheleEmdin
@AmrAbdin10 @KTamirisaMD @DrRajivsankar @JBauersachsMD @robmentz @TomLuscher @AndrewJSauer
@DrMarthaGulati @FedericaFogacci @afgcicero @glimongelli @IacopoOlivotto @HanCardiomd @GMCRosano @SeguraCardio @ShelleyZieroth @chiarabd @iamritu @cristinagavina @FeliceGragnano @rahatheart1 @gpontone1 @stefanocarugo @AnastasiaSMihai @radcliffeCARDIO @GCFmeeting

https://t.co/pCuZwdm0K7

[Dr Rishabh Jain @DrRishabhOnco]

🚨 TROPION-Breast01: It’s not just about PFS. The toxicity profile matters too.

The final safety and patient-reported outcomes analysis of TROPION-Breast01 shows that Datopotamab deruxtecan (Dato-DXd) offers a distinct toxicity profile compared with physician’s choice chemotherapy in previously treated HR+/HER2− metastatic breast cancer

Key findings:
✅ Grade ≥3 TRAEs: 22.2% vs 45.6%
✅ Delayed deterioration in:
• Global QoL
• Physical functioning
• Pain
✅ Less hematologic toxicity than chemotherapy

Watch for Dato-DXd toxicities:
• Stomatitis: 51.4% (Grade ≥3: 6.4%)
• Nausea: 51.9% (Grade ≥3: 1.4%)
• Ocular events/dry eye
• ILD: 3.9% overall (Grade ≥3: 0.8%, one grade 5 event)

Most patients received prophylactic mouthwash, antiemetics, and artificial tears, highlighting the importance of supportive care.

Bottom line:
Dato-DXd shifts toxicity from myelosuppression toward mucosal and ocular adverse events, while maintaining better patient-reported quality of life than standard chemotherapy. Appropriate prophylaxis and early toxicity management are essential.

📄 ESMO Open 2026 | TROPION-Breast01

#BreastCancer #Oncology #MedTwitter #TROPIONBreast01

@oncoalert @ASCO @myESMO

[Clinical Thyroidology @clinicalthyroid]

Read in the current issue: Which #thyroid #ultrasound risk system performs best? Dr. Robenshtok reviews comparison of 5 systems, highlighting trade-offs between #cancer detection and unnecessary #FNAs.
https://t.co/uTBGBGhH6l
#thyroidnodule #medtwitter #endotwitter #TIRADS

[Mike Rea @ThenIf_]

The word 'could' is doing a lot of lifting here...

Dig in: only 10 have actually reached pIII; the rest are earlier/ far less certain. Roche's own 5-year pIII success rate (58%) trails industry average (76%). Add in: several of these just entered pIII in '25/26 - a tight runway to clear trials, filing, and review by 2030 - and the realistic number of actual launches looks a lot closer to (low?) single digits than 19...

[Drew Moghanaki @DrewMoghanaki]

I’ve come to learn that most physicians pursue research ideas that someone else told them about. @sueyom @PBlanchardMD

[Ahmed Bennis MD 🫀 @drbennisahmed]

HFPEF 2026 ACC Expert Consensus Decision Pathway

HFpEF mimics? (if not noncardiac) — If the presentation warrants specific diagnostic workup → “HF attributed to” valvular disease, pericardial disease, infiltrative/restrictive myocardial disease, or ischemic heart disease.